Xpert膀胱癌监测尿液检测在非肌层浸润性膀胱癌随访中的纵向验证
研究纳入429例非肌层浸润性膀胱癌随访患者,评估Xpert尿液检测对肿瘤复发的预测价值。Xpert总体敏感性60.3%、特异性76.5%,高级别癌敏感性87%、阴性预测值99%。Xpert阳性而膀胱镜阴性者12个月内复发风险显著升高(所有肿瘤HR 2.68,高级别癌HR 6.84)。
要点
- Xpert对高级别癌敏感性87%、NPV 99%,适合排除高级别复发。
- Xpert阳性而膀胱镜阴性者12个月复发率32%,需密切随访。
- Xpert总体敏感性60.3%优于尿细胞学23.2%。
核心结论
- Xpert检测对膀胱癌复发具有高敏感性,对排除高级别癌具有高阴性预测值。
- Xpert阳性而膀胱镜阴性者复发风险高,需要密切监测。
研究设计与样本
- 前瞻性纵向随访研究,纳入429例非肌层浸润性膀胱癌监测患者。
- 患者接受Xpert、尿细胞学及UroVysion检测,Xpert阳性而膀胱镜阴性组66例与双阴性对照组随访12个月(±90天)。
主要发现
- 58例(13.5%)检出组织学确认的复发。
- Xpert总体敏感性60.3%、特异性76.5%;高级别癌敏感性87%、NPV 99%。
- 尿细胞学总体敏感性23.2%、特异性88.3%;高级别癌敏感性47.6%。
- Xpert阳性而膀胱镜阴性组12个月内32%(21例)复发,其中11例为高级别癌。
- 双阴性对照组12个月内14%(9例)复发,仅2例为高级别癌。
关键数值与推荐
- Xpert阳性而膀胱镜阴性组复发风险比:所有肿瘤HR 2.68,高级别癌HR 6.84。
临床怎么用
- Xpert可用于NMIBC随访中辅助排除高级别复发。
- Xpert阳性而膀胱镜阴性者应视为高危人群,需密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the performance of the Xpert Bladder Cancer Monitor (Xpert; Cepheid, Sunnyvale, CA, USA) test as a predictor of tumour recurrence in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Patients (n = 429) undergoing surveillance for NMIBC underwent Xpert, cytology, and UroVysion testing. Patients with a positive Xpert and a negative cystoscopy result (positive-negative [PN] group, n = 66) and a control group of double negative patients (negative Xpert and cystoscopy results [NN] group) were followed for 12 months (±90 days). RESULTS: Histology-confirmed recurrences were detected in 58 patients (13.5%). Xpert had an overall sensitivity of 60.3% and a specificity of 76.5%. The sensitivity for high-grade (HG) cancer was 87% with a negative predictive value (NPV) of 99%. Urine cytology showed an overall sensitivity of 23.2% (47.6% sensitivity for HG tumours) and a specificity of 88.3%. In the PN group, 32% (n = 21) developed a recurrence within 12 months, 11 of which were HG tumours. In the NN control group, 14% (n = 9) developed a recurrence and only two were HG tumours. The hazard ratio for developing recurrence in the PN group was 2.68 for all tumours and 6.84 for HG cancer. CONCLUSIONS: The Xpert test has a high sensitivity for detecting the recurrence of cancer and a high NPV for excluding HG cancer. In addition, the data suggest that patients with a positive Xpert assay in the setting of negative cystoscopy are at high risk for recurrence and need close surveillance.
引用
- Cowan B, Klein E, Jansz K, et al. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert® Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer. BJU Int. 2021. PMID: 33793062. doi:10.1111/bju.15418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。